Biohaven (NYSE:BHVN) Upgraded at William Blair

William Blair upgraded shares of Biohaven (NYSE:BHVN - Free Report) to a strong-buy rating in a report released on Thursday morning,Zacks.com reports.

Other equities research analysts also recently issued reports about the stock. JPMorgan Chase & Co. cut their price target on shares of Biohaven from $72.00 to $68.00 and set an "overweight" rating for the company in a report on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft set a $60.00 target price on Biohaven and gave the company a "buy" rating in a report on Thursday, March 20th. Royal Bank of Canada reiterated an "outperform" rating and issued a $61.00 target price on shares of Biohaven in a report on Tuesday, March 4th. Morgan Stanley dropped their price objective on Biohaven from $69.00 to $63.00 and set an "overweight" rating on the stock in a report on Friday, March 7th. Finally, HC Wainwright restated a "buy" rating and issued a $54.00 price objective on shares of Biohaven in a report on Tuesday, March 4th. Fourteen research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Biohaven currently has an average rating of "Buy" and an average price target of $62.54.

Biohaven Trading Up 0.7 %

BHVN stock traded up $0.15 during trading on Thursday, hitting $21.89. The company had a trading volume of 2,301,613 shares, compared to its average volume of 1,147,010. The firm has a market capitalization of $2.23 billion, a price-to-earnings ratio of -2.34 and a beta of 1.33. The business has a 50 day moving average of $25.73 and a 200 day moving average of $37.08. Biohaven has a fifty-two week low of $15.79 and a fifty-two week high of $55.70.

Biohaven (NYSE:BHVN - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.29). As a group, equities analysts predict that Biohaven will post -8.9 EPS for the current year.

Insider Activity

In other Biohaven news, Director John W. Childs bought 32,700 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were acquired at an average price of $30.47 per share, with a total value of $996,369.00. Following the completion of the purchase, the director now directly owns 2,320,571 shares in the company, valued at $70,707,798.37. The trade was a 1.43 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 16.00% of the stock is owned by company insiders.

Institutional Trading of Biohaven

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BHVN. JPMorgan Chase & Co. increased its stake in Biohaven by 144.5% in the fourth quarter. JPMorgan Chase & Co. now owns 1,979,169 shares of the company's stock valued at $73,922,000 after acquiring an additional 1,169,721 shares during the period. Norges Bank bought a new stake in Biohaven in the fourth quarter valued at about $33,711,000. Farallon Capital Management LLC grew its stake in Biohaven by 21.6% during the fourth quarter. Farallon Capital Management LLC now owns 4,428,167 shares of the company's stock worth $165,392,000 after buying an additional 785,578 shares during the last quarter. Janus Henderson Group PLC grew its stake in Biohaven by 12.1% during the fourth quarter. Janus Henderson Group PLC now owns 6,982,425 shares of the company's stock worth $260,735,000 after buying an additional 756,032 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in Biohaven by 8.1% during the fourth quarter. Vanguard Group Inc. now owns 8,414,120 shares of the company's stock worth $314,267,000 after buying an additional 628,211 shares during the last quarter. Institutional investors own 88.78% of the company's stock.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.